PPARG
LOCUS ID5468
GENE_SYMBOLPPARG
GENE NAMEperoxisome proliferator-activated receptor gamma
SYNONYMNSGLM1, CIMT1, NR1C3, PPARG1, PPARG2, PPARgamma
CHROMOSOME3
HOMOLOGENE ID7899
microRNAsNANA
GENE SUMMARY
This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are knownPPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Altertively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]

OBSERVATIONS

Complication Evidence PMID
Nephropathy1. Pro12Ala polymorphism of the PPARG gene may be associated with diabetic nephropathy among Asians. 2. Our results support an important association between rs1805192 minor allele (G allele) of PPARG and increased DN risk; the interaction analysis showed a combined effect of G allele?WC interaction between rs1805192 and abdominal obesity on DN risk. The possible synergistic effects between the genotype and abdominal obesity implied that a positive interaction between genetic and nongenetic factors may contribute to the development of DN in Chinese type 2 diabetic patients. 22103651, 28013303
Retinopathy1. Therapeutic targeting of PPARgamma may be beneficial to diabetic retinopathy. 2. Suppression of PPARgamma is involved in the pathogenesis of diabetic retinopathy and OIR. 3. We therefore hypothesized that the Gly482Ser polymorphism of the PPARGC1 gene and Pro12Ala polymorphism of the PPARgamma gene might confer susceptibility to diabetic retinopathy in type 2 diabetes. 4. Suppression of PPARgamma is involved in the pathogenesis of diabetic retinopathy and Oxygen-induced retinopathy OIR. DPH oxidase could be an upstream mediator of these changes.18309374 , 18806296 , 15782399
Atherosclerosis1. Thus in addition to the treatment of type II diabetes, PPARgamma agonists can be potentially employed for the treatment of atherosclerosis in general population 2. These findings suggest that PPARgamma activators, currently used in treatment of type II diabetes, may have beneficial effects in modulating inflammatory response in atherosclerosis. "12682906 , 10645917